



### Australian Government

Department of Health and Ageing Therapeutic Goods Administration

File Number: 2010/019541

Adam Guastella Brain and Mind Research Institute 100 Mallett Street CAMPERDOWN NSW 2050

### CTN Scheme (Drugs): Acknowledgement of New Trial - REPLACEMENT LETTER

Your notification to conduct a clinical trial under the Clinical Trial Notification (CTN) Scheme, pursuant to Schedule 5A of Regulation 12 of the Therapeutics Goods Regulations, has been received by the Office of Scientific Evaluation (OSE).

Trial Number: 2010/0622 Protocol Number: 13166

Drug(s):

Drug Active NameTrade NameCode NameStrengthOxytocinSyntocinonOT24 IU

#### It is noted that:

- i. the approval of the goods for this trial was given in accordance with Item 3 of Schedule 5A of the Therapeutic Goods Regulations by the body or organisation conducting the trial at each additional site.
- ii. the representative of the Ethics Committee for each additional site has certified that the Committee is constituted and operates in accordance with the NHMRC "National Statement on Ethical Conduct in Human Research" has considered this clinical trial, and has provided advice to the body or organisation conducting the trial.

The Therapeutic Goods Administration has not carried out an assessment of the quality, safety or efficacy of any drug product in relation to this notification.

Please note that, in the event that the Secretary of the Commonwealth Department of Health and Ageing becomes aware that to undertake or continue the clinical trial would be contrary to the public interest, the Secretary has the authority to direct that use of the drug product(s) for this clinical trial must cease.

A form "CTN Scheme (Drugs): Trial Completion Advice" is enclosed. Please fill out and return this form after the Clinical Trial has completed.

Sebastian Lavers

Experimental Products Section Office of Scientific Evaluation

19 January 2011



## Australian Government

# Department of Health and Ageing Therapeutic Goods Administration

# CTN Scheme (Drugs): Clinical Trial Site List

This document lists all sites acknowledged to date for the following clinical trial:

Sponsor: 14195 - University of Sydney

**Protocol Number: 13166** 

Trial Number: 2010/0622

Date Acknowledged Site Name State

16 December 2010 The University of Sydney - Brain & Mind Research Institute

NSW

Address: PO Box 100 Woden ACT 2606 Website: www.tga.gov.au Telephone: 02 6232 8101 Facsimile: 02 6232 8112 ABN 40 939 406 804



### **Australian Government**

### Department of Health and Ageing Therapeutic Goods Administration

# CTN Scheme (Drugs): Trial Completion Advice

Use this form to notify completion of a trial. Sponsor to complete. (Notification of completion should be made only after the trial has been completed at all sites. It is not necessary to notify completion dates for individual sites.)

# The following Clinical Trial has now been completed:

	0		
Sponsor:	14195	<ul> <li>University</li> </ul>	of Sydney

Protocol No: 13166

Trial Number: 2010/0622

Date Completed:				54
Completion Reason (Select one only):				
Concluded Normally	Premature term	ination - safety		
Insufficient Recruits	Premature termination - other			
Directed by HAC Secretary				
Other, please state				,
Print Name	Position			
Signature	Phone			
	Fax			
Please mail completed form to:				
Therapeutic Goods Administration P0 Box 100 Woden ACT 2606 Attention: EPS, Office of Scientific Evaluation	e ti			
Or Fax to (02) 6232 8112				